Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-10-01

FDA Approved: MAXALT-MLT — Supplemental Application (Organon LLC)

View source ↗

Summary

FDA approves a supplemental application for MAXALT-MLT (rizatriptan benzoate) from Organon LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MAXALT-MLT (Rizatriptan benzoate)

Snippet

SUPPL AP for MAXALT-MLT (RIZATRIPTAN BENZOATE)